LIP
JAZZ icon

Liontrust Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Liontrust Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-32,000
Closed -$657K – 218
2022
Q3 		$657K Buy
32,000
+26,000
+433% +$3.95M 0.01% 230
2022
Q2 		$936K Buy
+6,000
New +$924K 0.01% 224

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Liontrust Investment Partners's JAZZ Position: Q4 2022 in Review

Liontrust Investment Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2022, closing a stake of 32,000 shares — an estimated $657K sold.

Liontrust Investment Partners first reported a position in JAZZ in Q2 2022 and held it in 2 quarters. The position peaked at $936K in Q2 2022. 486 funds tracked by Wall St. Rank hold JAZZ as of Q4 2022.

  • Liontrust Investment Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Liontrust Investment Partners sold 32,000 Jazz Pharmaceuticals shares in Q4 2022, an estimated $657K.
  • Liontrust Investment Partners first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Liontrust Investment Partners's Jazz Pharmaceuticals position peaked at $936K in Q2 2022.
  • 486 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2022.

Based on Liontrust Investment Partners's 13F filing for Q4 2022, filed 14 Feb 2023.